p strong Haemonetics Corporation Reports First Quarter 2025 Financial Results strongpp Haemonetics

Haemonetics Corporation Reports First Quarter 2025 Financial Results

Haemonetics Corporation has reported its financial results for the first fiscal quarter ending June 29, 2024.

Key Financial Metrics

Haemonetics achieved a total revenue of $351 million for the first quarter of fiscal 2025. This was significantly above the Wall Street consensus estimate of $335.38 million for the same period. Specific EPS figures were not provided within the current excerpt.

Segment Revenue Performance

Unfortunately, a detailed breakdown of the revenue performance across major segments is not explicitly provided in the existing excerpt.

Dividends or Share Repurchase Program

Haemonetics did announce a share repurchase program in August 2022 authorizing the repurchase of up to $300.0 million of its common stock through August 2025. As of June 29, 2024, the total remaining authorization for repurchases under this program was $225.0 million.

Stock Price Movement

Following the earnings release, Haemonetics Corporation’s stock price saw an increase of approximately 2.34%.

In summary, Haemonetics Corporation has reported a robust financial performance for Q1 2025 with significant revenue surpassing Wall Street expectations. However, sections of the report relating to specific EPS figures and detailed segment revenue performance were not supplied in the current excerpt. Further details from company officers and guidance could provide additional insights into the overall performance and future expectations. The stock reacted positively to the earnings release, reflecting investor confidence.